Your browser doesn't support javascript.
loading
Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target.
Smati, Sarra; Polizzi, Arnaud; Fougerat, Anne; Ellero-Simatos, Sandrine; Blum, Yuna; Lippi, Yannick; Régnier, Marion; Laroyenne, Alexia; Huillet, Marine; Arif, Muhammad; Zhang, Cheng; Lasserre, Frederic; Marrot, Alain; Al Saati, Talal; Wan, JingHong; Sommer, Caroline; Naylies, Claire; Batut, Aurelie; Lukowicz, Celine; Fougeray, Tiffany; Tramunt, Blandine; Dubot, Patricia; Smith, Lorraine; Bertrand-Michel, Justine; Hennuyer, Nathalie; Pradere, Jean-Philippe; Staels, Bart; Burcelin, Remy; Lenfant, Françoise; Arnal, Jean-François; Levade, Thierry; Gamet-Payrastre, Laurence; Lagarrigue, Sandrine; Loiseau, Nicolas; Lotersztajn, Sophie; Postic, Catherine; Wahli, Walter; Bureau, Christophe; Guillaume, Maeva; Mardinoglu, Adil; Montagner, Alexandra; Gourdy, Pierre; Guillou, Hervé.
Afiliación
  • Smati S; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Polizzi A; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Fougerat A; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Ellero-Simatos S; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Blum Y; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Lippi Y; CIT, Ligue Nationale Contre Le Cancer, Paris, France.
  • Régnier M; IGDR UMR 6290, CNRS, Université de Rennes 1, Rennes, France.
  • Laroyenne A; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Huillet M; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Arif M; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Zhang C; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Lasserre F; Science for Life Laboratory, KTH-Royal Institute of Technology, Solna, Sweden.
  • Marrot A; Science for Life Laboratory, KTH-Royal Institute of Technology, Solna, Sweden.
  • Al Saati T; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Wan J; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Sommer C; Experimental Histopathology Department, INSERM US006-CREFRE, University Hospital of Toulouse, Toulouse, France.
  • Naylies C; INSERM-UMR1149, Centre de Recherche sur l'Inflammation, Paris, France.
  • Batut A; Sorbonne Paris Cité, Laboratoire d'Excellence Inflamex, Faculté de Médecine, Site Xavier Bichat, Université Paris Diderot, Paris, France.
  • Lukowicz C; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Fougeray T; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Tramunt B; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Dubot P; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Smith L; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Bertrand-Michel J; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Hennuyer N; Laboratoire de Biochimie Métabolique, CHU Toulouse, Toulouse, France.
  • Pradere JP; INSERM U1037, CRCT, Université Paul Sabatier, Toulouse, France.
  • Staels B; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Burcelin R; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Lenfant F; Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France.
  • Arnal JF; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Levade T; Univ. Lille, INSERM, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000, Lille, France.
  • Gamet-Payrastre L; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Lagarrigue S; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Loiseau N; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), UMR1297, INSERM/UPS, Université de Toulouse, Toulouse, France.
  • Lotersztajn S; Laboratoire de Biochimie Métabolique, CHU Toulouse, Toulouse, France.
  • Postic C; INSERM U1037, CRCT, Université Paul Sabatier, Toulouse, France.
  • Wahli W; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Bureau C; INRAE, INSTITUT AGRO, PEGASE UMR1348, 35590, Saint-Gilles, France.
  • Guillaume M; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
  • Mardinoglu A; INSERM-UMR1149, Centre de Recherche sur l'Inflammation, Paris, France.
  • Montagner A; Sorbonne Paris Cité, Laboratoire d'Excellence Inflamex, Faculté de Médecine, Site Xavier Bichat, Université Paris Diderot, Paris, France.
  • Gourdy P; Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France.
  • Guillou H; Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, Toulouse, France.
Gut ; 71(4): 807-821, 2022 04.
Article en En | MEDLINE | ID: mdl-33903148
ABSTRACT

OBJECTIVE:

We evaluated the influence of sex on the pathophysiology of non-alcoholic fatty liver disease (NAFLD). We investigated diet-induced phenotypic responses to define sex-specific regulation between healthy liver and NAFLD to identify influential pathways in different preclinical murine models and their relevance in humans.

DESIGN:

Different models of diet-induced NAFLD (high-fat diet, choline-deficient high-fat diet, Western diet or Western diet supplemented with fructose and glucose in drinking water) were compared with a control diet in male and female mice. We performed metabolic phenotyping, including plasma biochemistry and liver histology, untargeted large-scale approaches (liver metabolome, lipidome and transcriptome), gene expression profiling and network analysis to identify sex-specific pathways in the mouse liver.

RESULTS:

The different diets induced sex-specific responses that illustrated an increased susceptibility to NAFLD in male mice. The most severe lipid accumulation and inflammation/fibrosis occurred in males receiving the high-fat diet and Western diet, respectively. Sex-biased hepatic gene signatures were identified for these different dietary challenges. The peroxisome proliferator-activated receptor α (PPARα) co-expression network was identified as sexually dimorphic, and in vivo experiments in mice demonstrated that hepatocyte PPARα determines a sex-specific response to fasting and treatment with pemafibrate, a selective PPARα agonist. Liver molecular signatures in humans also provided evidence of sexually dimorphic gene expression profiles and the sex-specific co-expression network for PPARα.

CONCLUSIONS:

These findings underscore the sex specificity of NAFLD pathophysiology in preclinical studies and identify PPARα as a pivotal, sexually dimorphic, pharmacological target. TRIAL REGISTRATION NUMBER NCT02390232.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies Idioma: En Revista: Gut Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Prognostic_studies Idioma: En Revista: Gut Año: 2022 Tipo del documento: Article